CervoMed (NASDAQ:CRVO) Stock Price Expected to Rise, Chardan Capital Analyst Says

CervoMed (NASDAQ:CRVO) had its price target hoisted by analysts at Chardan Capital from $15.00 to $21.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Chardan Capital’s target price points to a potential upside of 396.45% from the stock’s current price.

Several other analysts also recently issued reports on the stock. Zacks Research raised shares of CervoMed from a “strong sell” rating to a “hold” rating in a report on Monday, January 12th. Cantor Fitzgerald initiated coverage on shares of CervoMed in a research report on Thursday, December 18th. They set an “overweight” rating for the company. HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of CervoMed in a report on Thursday, December 18th. raised CervoMed to a “strong-buy” rating in a research report on Tuesday, February 3rd. Finally, D. Boral Capital reiterated a “buy” rating and issued a $31.00 price objective on shares of CervoMed in a research note on Monday. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $23.00.

CervoMed Stock Performance

CRVO opened at $4.23 on Wednesday. The firm has a market cap of $39.17 million, a P/E ratio of -1.42 and a beta of -0.77. The business has a 50 day moving average price of $5.21 and a 200 day moving average price of $7.19. CervoMed has a twelve month low of $3.58 and a twelve month high of $16.94.

CervoMed (NASDAQ:CRVO) last announced its quarterly earnings results on Friday, March 13th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.79) by ($0.09). CervoMed had a negative net margin of 672.80% and a negative return on equity of 96.04%. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.84 million. As a group, analysts anticipate that CervoMed will post -1.88 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CervoMed

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Rhumbline Advisers raised its position in shares of CervoMed by 35.5% during the first quarter. Rhumbline Advisers now owns 5,830 shares of the company’s stock valued at $53,000 after buying an additional 1,526 shares during the last quarter. State Street Corp lifted its stake in shares of CervoMed by 11.4% in the fourth quarter. State Street Corp now owns 20,527 shares of the company’s stock valued at $162,000 after buying an additional 2,100 shares during the period. Thompson Davis & CO. Inc. grew its position in CervoMed by 20.8% during the third quarter. Thompson Davis & CO. Inc. now owns 16,850 shares of the company’s stock worth $136,000 after buying an additional 2,900 shares in the last quarter. Vanguard Group Inc. increased its stake in CervoMed by 1.0% during the third quarter. Vanguard Group Inc. now owns 343,463 shares of the company’s stock valued at $2,779,000 after acquiring an additional 3,445 shares during the period. Finally, Citizens Financial Group Inc. RI increased its stake in CervoMed by 14.2% during the third quarter. Citizens Financial Group Inc. RI now owns 30,477 shares of the company’s stock valued at $247,000 after acquiring an additional 3,800 shares during the period. Institutional investors own 25.15% of the company’s stock.

Trending Headlines about CervoMed

Here are the key news stories impacting CervoMed this week:

• Positive Sentiment: New clinical data presented at the AD/PD 2026 conference show that neflamapimod produced greater benefit in Dementia with Lewy Bodies (DLB) patients who have low plasma pTau181 (i.e., likely without Alzheimer’s co‑pathology). This can increase the perceived commercial and regulatory value of the program for a clearer DLB target population. GlobeNewswire: AD/PD 2026 Data
• Positive Sentiment: HC Wainwright reiterated a Buy and a $25 price target while trimming some near-term EPS forecasts but raising several quarterly and FY2026/FY2027 estimates overall (and raising some quarter estimates). The firm’s maintained Buy and higher longer‑term estimates support upside expectations. MarketBeat: HC Wainwright Notes
• Positive Sentiment: Chardan Capital raised its price target from $15 to $21 and kept a Buy rating, signaling investor conviction from another boutique healthcare analyst. TickerReport: Chardan Raise
• Positive Sentiment: D. Boral Capital published a Buy rating on CRVO, adding to the list of brokers expressing conviction in the story. American Banking News: Buy Rating
• Neutral Sentiment: Coverage notes and press summaries report the company was “flat” on Q4/FY results; no new material guidance or financing announcements were reported in those summaries. Market reaction may therefore hinge on interpretation of pipeline updates and analyst notes. BayStreet: Flat on Q4/FY
• Neutral Sentiment: Reported short‑interest data for March are effectively meaningless in the published entry (shows 0 shares / NaN change), so short‑squeeze or added short pressure is not an active driver based on that report.
• Negative Sentiment: Roth MKM lowered its price target from $19 to $11 (while still on Buy), which reduces near‑term analyst upside and could pressure sentiment among investors focused on published targets. Benzinga: Roth MKM PT Cut
• Negative Sentiment: HC Wainwright trimmed its Q1 2026 EPS estimate (worse near‑term quarterly view), underscoring continued execution and cash‑burn risk until definitive late‑stage data or partnering/financing alleviates funding concerns.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.